AzurRx BioPharma, Inc. — 2017 Form 10-K Summary
Entity and period: The supplied filing is AzurRx BioPharma, Inc.’s annual report for the fiscal year ended December 31, 2017, filed March 16, 2018. This does not match the request metadata naming Gridai Technologies Corp. or describing the period as 2017 Q4. The filing identifies the company as a development-stage biopharmaceutical business listed on Nasdaq as AZRX.
Business context and pipeline
AzurRx develops non-systemic biologics for gastrointestinal disorders and reported no product revenue. Its lead candidate, MS1819, is a yeast-derived lipase being studied for exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis. Its Phase II dose-escalation study was enrolling in Australia, New Zealand, and France. AZX1101, intended to protect the gut microbiome from certain intravenous antibiotics, remained in preclinical development.
Financial results and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.40 million | $2.50 million |
| General and administrative expense | $7.69 million | $4.13 million |
| Operating loss | $10.22 million | $6.33 million |
| Net loss | $11.10 million | $14.59 million |
| Basic and diluted loss per share | $1.04 | $2.24 |
| Cash used in operating activities | $7.18 million | $4.53 million |
| Cash at year-end | $573,471 | $1.77 million |
Margins are not meaningful because the company had no revenue. The 2017 net loss narrowed year over year mainly as interest expense declined substantially, while operating loss widened because G&A rose; R&D expense decreased modestly. G&A growth included noncash stock and warrant costs and higher public-company, personnel, investor-relations, legal, audit, and insurance expenses.
At December 31, 2017, total assets were $5.48 million, total liabilities $3.82 million, and stockholders’ equity $1.66 million. Current assets were $1.95 million versus current liabilities of $2.48 million, yielding negative working capital of approximately $527,000. Other receivables were $1.10 million, including $955,000 of French R&D tax credits. The filing reports $387,200 of convertible debentures, including accrued interest, due July 11, 2018; the balance-sheet carrying amount for convertible debt was $257,365 after debt discount. Note payable was $159,180. Contractual operating lease payments totaled $233,386.
Changes, financing, and unusual items
- Net loss improved by about $3.50 million versus 2016, but operating loss increased by about $3.90 million. Interest expense fell to $875,199 from $5.94 million, largely reflecting less outstanding prior-year OID debt; the 2016 results also included a $2.33 million warrant fair-value loss.
- The 2017 private placement generated approximately $5.0 million gross proceeds, with additional units sold for $400,000. The company also issued a 12% senior secured convertible debenture to Lincoln Park Capital. These financings and conversions increased the common shares outstanding to 12,042,574 at year-end from 9,631,088 a year earlier.
- In January 2018, warrant exercises generated approximately $2.2 million in proceeds, which management included in its runway estimate. The company stated this funding was expected to sustain operations only until September 2018.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, negative operating cash flow, negative working capital, and dependence on additional external financing. The independent auditor issued an unmodified opinion but also included a going-concern paragraph.
- The 2017 Tax Act reduced the U.S. corporate rate and led to an estimated $2.24 million reduction in deferred tax assets; a full valuation allowance remained, so there was no 2017 income-statement tax benefit. No material pending legal proceedings were disclosed.
Outlook, commentary, and principal risks
- Management expected MS1819 Phase II study results in the second half of 2018 and planned further FDA discussions and an IND submission in the latter half of 2018. It also expected to file an IND for AZX1101 in 2018. These are forward-looking targets, not assurances.
- The company expected R&D and G&A expenses to increase as development advances. It said substantial additional funding would be needed and that failure to raise capital could force it to delay, curtail, or eliminate development programs.
- Key risks include clinical and regulatory failure or delay, patient enrollment, dependence on contract manufacturers and research organizations, licensing and intellectual-property risks, competition, and the ability to obtain financing. The filing also cites dilution, debt-default risk, and limited trading liquidity.
- Management reported effective disclosure controls and internal control over financial reporting. The auditor did not provide an attestation on internal control.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied document is AzurRx BioPharma, Inc.’s 2017 Form 10-K, not a Gridai Technologies Corp. filing.
- Assess whether available cash and subsequent warrant proceeds were sufficient to meet obligations and fund operations beyond the stated September 2018 runway; verify subsequent financing and debt repayment or restructuring.
- Track MS1819 clinical results and the timing and status of planned FDA submissions, along with AZX1101’s preclinical progress and IND plans.
- Review the composition and collection timing of the $1.10 million of other receivables, especially French R&D tax credits, and monitor the $387,200 debenture obligation due July 2018.
- Evaluate potential dilution from warrants, options, convertible debt, and the $1.07 million year-end stock-subscription receivable; also reconcile reported private-placement net proceeds across the filing’s discussion and financial statements.